Drug Discovery
By
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
Will Johnson & Johnson’s FDA Approval of INLEXZO™ Redefine Bladder Cancer Care After 40 Years of Limited Progress?
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical system), marking the…
Could Johnson & Johnson’s MARIPOSA Trial with RYBREVANT® + LAZCLUZE® Transform First-Line EGFR-Mutated NSCLC Treatment?
Key Highlights: Clinical Breakthrough in EGFR-Mutated NSCLCJohnson & Johnson’s Innovative Medicine segment has announced positive results from the…
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food Noise’ Control, Body Composition, and Cardiovascular Outcomes?
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes and obesity portfolio…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal Zone Lymphoma Patients?
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
Does a New Kidney Cancer Trial Expand Long-Term Oncology Optionality for Bristol-Myers Squibb and BioNTech?
December 2025 — Bristol-Myers Squibb and BioNTech have announced progress in their oncology collaboration with the initiation of…
